UN PORTALE PER “BUCARE” IL MURO DEL PAGAMENTO ED ARRIVARE ALLE PUBBLICAZIONI. DA QxMD
A portal to the papers beyond paywalls QxMD Bets are a paywall has stopped you from reading a paper at…
Approfondisci...
ODDS VS PROBABILITA’ : UN MINUTO PER COMPRENDERE LA DIFFERENZA E PASSARE DALL’UNO ALL’ALTRA !
Odds != Probability Keith McNulty (Expert and Author in Applied Mathematics, Data Science, Statistics and Psychometrics. Find me on LinkedIn…
IL NUOVO RISCHIO CARDIOVASCOLARE “SCORE2 risk calculator”: UN INTERVISTA AL PRINCIPALE AUTORE, IL PROF. EMANUELE DI ANGELOANTONIO
Global Spotlights A cardiovascular risk calculator to save millions of lives Mark Nicholls* It is a collaboration of about 200…
LO SVILUPPO DEL “TOOL” UpPRIORITY PER RIDURRE LO SPRECO DI META-ANALISI E LINEE GUIDA. QUALE PROBLEMA CLINICO MERITA ATTENZIONE? (2017)
Development of a prioritisation tool for the updating of clinical guideline questions: the UpPriority Tool protocol Laura Martínez García et…
IL MODELLO UpPRIORITY E’ DI GRANDE UTILITA’ PER IDENTIFICARE LE AREE DI RICERCA DI META-ANALISI E LINEE GUIDA.
The UpPriority tool supported prioritization processes for updating clinical guideline questions Andrea Juliana Sanabria et al. Abstract Objective: We aim to…
PER RIDURRE LO SPRECO DEI TEST PRE-OPERATORI. UN EDITORIALE DI “JAMA”
Moving Beyond Guidelines—Use of Value-Based Preoperative Testing Niloofar Latifi, et al. In 2010, the Institute of Medicine estimated that the annual…
L’AFRICA SI ORGANIZZA PER UNO STANDARD DELLE DIVERSE LINGUE NELLA RICERCA SCIENTIFICA. DA “NATURE” IL PROGETTO “DECOLONIZE SCIENCE”
African languages to get more bespoke scientific terms Many words common to science have never been written in African languages.…
TALORA SUCCEDE…HONESTY !? SCIENCE RACCONTA
A Famous Honesty Researcher Is Retracting A Study Over Fake Data Renowned psychologist Dan Ariely literally wrote the book on…
POVERA EBM: I DUBBI SULL’ULTIMO TRIAL ANTI COVID-19. RIDUZIONE DELLA MORTALITA’ DEL 77% ? DA “SCIENCE”
‘Too good to be true’: Doubts swirl around trial that saw 77% reduction in COVID-19 mortality Robert F. Service Science’s…
INTRODUZIONE ALLA ANALISI STATISTICA DEI DATI CLINICI IN 15′ MINUTI! PROVARE PER CREDERE
Statistical Analysis of Biomedical Data — an Overview From p-values and regression to clustering and classification Sukanta Saha The last…
GLI INIBITORI DELLA POMPA PROTONICA “PROTEGGONO” DAL DIABETE ? UNA IPOTESI ED UNA META-ANALISI INTERESSANTE
Effects of Proton Pump Inhibitors on Glycemic Control and Incident Diabetes: A Systematic Review and Meta-Analysis Carol Chiung-Hui Peng et…
SEI UN “BAYESIANO” OD UN “FREQUENTISTA” ? VERIFICA IL TUO ALLINEAMENTO DA “TOWARDS DATA SCIENCE” !
Statistics: Are you Bayesian or Frequentist? The fastest way to diagnose your statistical alignment Cassie Kozyrkov What if I told…
“LIKELIHOOD RATIO” PER INTERPRETARE MEGLIO I TRIAL CLINICI: NON LO SAPEVATE ?!
How to use likelihood ratios to interpret evidence from randomized trials Thomas V.Perneger Highlights • The likelihood ratio represents evidence from…
IL CONCETTO DI “NET BENEFIT” : OCCHIO A TUTTI GLI OUTCOME!
The Net Benefit of a treatment should take the correlation between benefits and harms into account Marc Buyse et al.…
I PRIMI 100 GIORNI DEL COVID-19: LA EBM RISCHIA LA “DEBACLE”
Recruitment and Results Reporting of COVID-19 Randomized Clinical Trials Registered in the First 100 Days of the Pandemic Perrine Janiaud,…
IL CAFFE’ RIDUCE IL RISCHIO DI FIBROSI E DI CIRROSI: UNA META-ANALISI
CIRROSI EPATICA, EPATOLOGIA, GASTROENTEROLOGIA, MEDICI DI FAMIGLIA, MEDICINA INTERNA, METODOLOGIA, NUTRIZIONEBy Redazione
Coffee Consumption Decreases Risks for Hepatic Fibrosis and Cirrhosis: A Meta-Analysis Fen Liu et al. Abstract Background and Aim Previous…
LE PUBBLICAZIONI “PRE-PRINT” DISTURBANO LA EBM: UN COMMENTO SULLE REVIEWS IN TEMPI DI COVID-19
Using Preprints in Evidence Synthesis: Commentary on experience during the COVID-19 pandemic Barbara Clyne et al. Introduction SARS-CoV-2, the virus…
IL COVID HA INTERROTTO IL CORRETTO FLUSSO DELLE EVIDENZE: UNA RIFLESSIONE SU “NATURE”
GLOBAL HEALTH, INTERNATIONAL SNAPSHOTS, MEDICI DI FAMIGLIA, MEDICINA INTERNA, METODOLOGIA, REAL WORLD EVIDENCEBy Redazione
HOW COVID BROKE THE EVIDENCE PIPELINE The pandemic stress-tested the way the world produces evidence — and revealed all the…
BAYES E VACCINO PFIZER-BIONTECH: UNA ATTENTA ANALISI SULLA EFFICACIA. DO YOU BAYES ? PARTE SECONDA
Bayesian Statistics of Efficacy of Pfizer-BioNTech COVID-19 Vaccine — part II Reproducing original results Bartek Skorulski Part II (this post)…
BAYES E VACCINO PFIZER-BIONTECH: UNA ATTENTA ANALISI SULLA EFFICACIA. DO YOU BAYES ? PARTE PRIMA
Bayesian Statistics of Efficacy of the Pfizer-BioNTech COVID-19 Vaccine — part I Vaccine Efficacy and Beta-binomial model Bartek Skorulski Posterior…
UNA DELLE PIU’ BELLE INTRODUZIONI ALLA ANALISI BAYESIANA. DO YOU BAYES?
The Gentlest of Introductions to Bayesian Data Analysis How to think in a natural way based on data Michał Oleszak…
NUOVA MODALITA’ PER IL REPORT DI META-ANALISI : “PRISMA STATEMENT ” 2020
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews Matthew J. Page et al. Abstract The Preferred Reporting…
MORTALITA’ PER COVID-19 E PER ALTRE CAUSE ! USA 2020-2021
Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021 Steven H. Woolf…
IL BENEFICIO IN TERMINI DI SOPRAVVIVENZA E’ RIDOTTO AD ASSENTE PER I FARMACI ONCOLOGICI APPROVATI : L’ESPERIENZA CANADESE
Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada Daniel E. Meyers et al.…
